Invention Summary
The chemical inhibitors developed selectively target cancer cells with stem cell properties (cancer stem cells) and have no effect on normal somatic cells. The presence of Sox2—a unique tumor marker—is identified in various lung, breast, ovarian, gastric, brain, leukemia, kidney, and liver cancers, and is sufficient to confer sensitivity to the chemical inhibitors. LSD1 and HDAC1 inhibitors are used to inhibit the growth of Sox2-expressing cancer cells and cancer stem cells.
Market Opportunity
Sox2 is identified not only in lung, breast, ovarian, brain, colon, brain, liver, gastric, and kidney carcinomas, but also in other blood born cancers such as leukemia. Currently, there is no cancer therapy for Sox2-expressing cancers. Targeting cancer cells with stem cell properties is an unmet medical demand because these cancer cells are usually more resistant to conventional chemo and radiation therapy, causing high recurrence.
● The method identifies the existence of Sox2 stem cell markers in a patient and introduces the chemical inhibitors to suppress gene expression of cancer cells.
● The inhibitors are given to the patient by infusion, perfusion, ingestion, or intravenous introduction, and by application of a liquid or gel. The liquid or gel comprises a transdermal carrier.
由于技术保密工作限制,技术信息无法完全展现,请通过邮箱或短信联系我们,获取更多技术资料。
stem cell properties
market opportunity sox2
unmet medical demand
causing high recurrence
normal somatic cells
